title: Prevention of tissue necrosis due to accidental extravasation of cytostatic drugs by a conservative approach.
abstract: The purpose of the present study was to evaluate comparatively the effectiveness of a conservative approach to treatment, using two therapeutic schedules (with and without sodium thiosulfate (ST), so as to minimize necrosis due to drug extravasation and to avoid the need for reconstructive surgery. The 63 patients entered into this study were separated into two groups; these in group A were treated with hydrocortisone and dexamethasone, and these in group B received the combination plus ST. In both groups, the drugs that had extravasated included doxorubicin, epirubicin, vinblastine, mitomycin C. The healing time varied with the different drugs used and was proportional to the extent of extravasation and to the time at which therapy was begun. The mean healing time for group B, which received ST was about half that for group A, which did not. We conclude that the application of conservative measures during chemotherapy may prevent tissue necrosis due to drug extravasation and the subsequent need for reconstructive surgery. The administration of ST can help in the achievement of this goal.
authors.affiliation: Second Department of Medical Oncology Metaxa Cancer Hospital, Piraeus, Greece.
authors.forename: N B
authors.initials: NB
authors.lastname: Tsavaris
authors.forename: P
authors.initials: P
authors.lastname: Komitsopoulou
authors.forename: P
authors.initials: P
authors.lastname: Karagiaouris
authors.forename: P
authors.initials: P
authors.lastname: Loukatou
authors.forename: I
authors.initials: I
authors.lastname: Tzannou
authors.forename: N
authors.initials: N
authors.lastname: Mylonakis
authors.forename: P
authors.initials: P
authors.lastname: Kosmidis
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000931:Antidotes / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D003907:Dexamethasone / Q000627:therapeutic use; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects; D004359:Drug Therapy, Combination; D005119:Extravasation of Diagnostic and Therapeutic Materials / Q000188:drug therapy; D005260:Female; D006801:Humans; D006854:Hydrocortisone / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009336:Necrosis; D012867:Skin / Q000187:drug effects / Q000473:pathology; D012871:Skin Diseases / Q000139:chemically induced / Q000517:prevention & control*; D013885:Thiosulfates / Q000627:therapeutic use*
chemical_list: D000931:Antidotes; D000970:Antineoplastic Agents; D013885:Thiosulfates; D003907:Dexamethasone; D004317:Doxorubicin; C017717:sodium thiosulfate; D006854:Hydrocortisone